Eletriptan

FDA label

Read the full label on DailyMed ↗

Renal Undefined

Hepatic Severe: not recommended (not evaluated); mild-moderate not specifically addressed

Second dose no sooner than 2 h after first; max 80 mg per 24 h

Instructions

• May repeat once ≥2 h after first dose if no response or recurrence; do not exceed 80 mg in 24 h.
• Do not treat an average of more than 3 migraine attacks per 30 days (not established).

Contraindications

• Ischemic coronary artery disease or coronary vasospasm (incl. Prinzmetal's angina)
• Wolff-Parkinson-White syndrome or arrhythmias with other accessory conduction pathway disorders
• History of stroke or TIA, or hemiplegic or basilar migraine
• Peripheral vascular disease
• Ischemic bowel disease
• Uncontrolled hypertension
• Use within 24 h of another 5-HT1 agonist or ergotamine/ergot-type medication
• Use within 72 h of potent CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, clarithromycin, ritonavir, nelfinavir)

Cautions

• Myocardial ischemia/infarction and Prinzmetal's angina — cardiac evaluation in high-risk patients
• Arrhythmias — discontinue if they occur
• Chest/throat/neck/jaw pain or pressure
• Cerebrovascular events
• GI and peripheral vasospastic reactions
• Medication overuse headache
• MAOIs due to risk of serotonin syndrome
• Blood pressure increase

Adverse reactions

• Asthenia
• Nausea
• Dizziness
• Somnolence

Pregnancy Insufficient human data; animal developmental toxicity at clinically relevant doses.

Lactation Excreted in human milk; minimize infant exposure by avoiding breastfeeding for 24 h after treatment.